Sakar Healthcare Limited (SAKAR)
Investor Presentation
Investor Presentation - Q2 & H1FY27
- Revenue grew 52% y-y in Q2FY27 to INR 87.4 Cr; H1FY27 revenue up 45% y-y to INR 160.4 Cr
- EBITDA margin improved to 28% in Q2FY27 from 20% in Q2FY26; H1FY27 EBITDA margin at 28%
- PAT rose 149% y-y in Q2FY27 to INR 11.3 Cr; H1FY27 PAT up 134% y-y to INR 21.6 Cr
- Oncology portfolio expanded with 69 contracts executed and 45 ongoing discussions; 22 global marketing authorizations granted
- Integrated API and FDF oncology facility operational, supporting higher margin and supply chain control
- 33 tech transfer projects underway; 21 APIs developed in-house with 16 regulatory confirmations
- Company progressing towards regulatory-driven, vertically integrated business model with global market presence
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 SAKAR — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add SAKAR to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Sakar Healthcare Limited
Important.
The summary above is generated automatically from Sakar Healthcare Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.